Protea, VCU Sign Deal to Combine LAESI Technology with Other Molecular Imaging Approaches | GenomeWeb

NEW YORK (GenomeWeb News) – Protea Biosciences said today that it has entered into a collaborative research agreement with Virginia Commonwealth University and its Center for Molecular Imaging focused on improved molecular imaging techniques for the study of cancer, Alzheimer's, and other diseases.

Under the collaboration, the parties will work to combine Protea's ex vivo molecular imaging mass spectrometry technology, Laser Ablation Electrospray Ionization, or LAESI, with VCU's in vivo molecular PET, SPECT and MRI/MRS imaging capabilities.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.